MOTS-c gets talked about as an exercise mimetic, something that turns on the same mitochondrial signaling exercise does. It's also one of the newer compounds on this site, which matters for dosing: nothing about how much people run traces to a human dose-finding study, because none exists yet. Below is the amount most commonly discussed, honestly framed as convention rather than evidence, how it's cycled and stacked, and how it compares to SS-31.
Vial size isn't part of what follows, since the amount of bacteriostatic water you add sets your concentration either way. Our reconstitution calculator handles that math for whatever vial and target dose you're working with.
What it is
MOTS-c is a small peptide encoded inside mitochondrial DNA rather than the regular cell nucleus, which is unusual for a signaling molecule and part of why it draws so much attention. It naturally circulates in the bloodstream and rises during exercise, which is where the "exercise mimetic" framing comes from. It's sold as a research chemical, not an FDA-approved drug or supplement, and no controlled human study of an administered amount has been published as of this writing.
What people use it for
MOTS-c shows up mainly in metabolic health and insulin sensitivity conversations, alongside a general interest in exercise capacity and age-related metabolic slowdown. A smaller, more forward-looking interest sits in cellular stress signaling and longevity research, tied to its role as a mitochondria-derived messenger. All of this interest is currently built on animal and cell research plus observed patterns in human blood, not on a study of giving people the compound directly.
Formulations
MOTS-c ships as a lyophilized (freeze-dried) powder that needs reconstitution before use. Vendors most commonly sell 2 mg and 5 mg vials, with 10 mg less common. There's no oral or nasal commercial formulation, so subcutaneous injection of the reconstituted solution is the route people run.
Dosing protocols
There's no settled dose for MOTS-c, and it's worth being direct about why: no human study has ever tested giving someone a specific amount and measured what happened. What circulates instead is entirely a research-community convention, extrapolated from animal work and informal use rather than traced to any trial.
See the MOTS-c research notes for more background before reading the dosing itself.
Most commonly referenced pattern
5 to 10 mg weekly, split across 2 to 3 injections rather than given all at once. This is the shape referenced most often across vendor and community dosing guides, generally without a named source behind the specific figure.
A slower, titrated variant
Starting around 2.5 to 5 mg two to three times weekly, then increasing over 4 to 6 weeks toward the 10 mg, five-times-weekly range some sources describe as a maintenance amount. Framed as a gentler way in, with the same lack of traceable origin as the pattern above.
Because MOTS-c rises naturally during physical activity, some sources tie dosing days to exercise days, on the reasoning that timing an injection near a workout mirrors when the body would produce more of it anyway. That's a mechanism-based idea, not a tested finding, and no source we found claims otherwise.
Cycling guidelines
Eight to twelve weeks on, followed by four to six weeks off, is the pattern most commonly described, reasoned as a way to avoid the body adapting to constant exposure. We couldn't find a source for where that specific ratio came from.
Signs a course is commonly stopped early:
- Persistent injection-site reaction beyond mild, brief redness
- Any new symptom you can't otherwise explain
- Unusual changes in blood sugar or energy that don't resolve
Stacking
Most commonly paired stack: MOTS-c and SS-31.
Rationale: both work on mitochondrial function through different angles, cellular energy signaling for MOTS-c, structural protection of the mitochondria's inner membrane for SS-31, which is why the two get discussed together constantly in longevity-adjacent conversations.
Protocol as run: each peptide on its own schedule from above, run over the same general weeks rather than on one matched timetable.
Why it's paired: the mitochondrial framing is the whole draw for both compounds, so people researching one tend to look at the other, not because a combination has been studied together.
Lighter stacks: some longevity-focused stacks add MOTS-c alongside NAD+-adjacent compounds, on the reasoning that cellular energy and mitochondrial signaling overlap. This is rationale plus a loosely matched schedule, not a protocol with dedicated combination data.
Combinations to approach carefully: stacking MOTS-c with other compounds that affect blood sugar or insulin signaling is worth extra attention, since MOTS-c's proposed mechanism touches the same pathways, and no source addresses what layering that effect actually does.
Expected results timeline
Early days: mostly an adjustment period for the injection routine itself. Anything noticed in the first several days is more likely the routine or placebo than the compound doing its work.
During a course: this is where most self-reported changes cluster, energy and exercise capacity, entirely self-reported and not measured against a control group.
Cumulative, across repeated courses: any metabolic-marker change would only show up here, and it's the piece with the least real-world evidence behind it, since the underlying data is animal and cell work, not people.
What to expect realistically: a compound with a genuinely interesting mechanism and, right now, no human dosing study behind any of the numbers in circulation. Energy or exercise-capacity changes are the most commonly described signal. A measurable metabolic change without lab testing isn't a reasonable expectation.
Administration technique
- The lyophilized powder is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for the target dose.
- The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptide.
- The calculated volume is drawn into an insulin syringe.
- A subcutaneous site is chosen, commonly the abdomen, with sites rotated across the week.
- The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
- Each injection is commonly logged by date, amount, and site, so a multi-week course doesn't rely on memory partway through.
Side effects and safety
Common: mild redness or irritation at the injection site.
Less common: mild changes in appetite or energy reported anecdotally, not measured in any controlled way.
What we don't know: there's no completed human safety study for administered MOTS-c. Everything about tolerability at any given amount is inference from animal work and informal reports, not established safety data. Treat that as a real open question, not a settled one.
Contraindications: anyone managing diabetes or another blood-sugar condition should be especially cautious, given the compound's proposed role in insulin sensitivity. Pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.
Drug interactions: none have been formally characterized. Given the proposed effect on insulin sensitivity, an interaction with medications that also affect blood sugar is a reasonable mechanism-based caution rather than a documented finding.
MOTS-c vs. SS-31
If you're weighing MOTS-c against something else, SS-31 is the compound people actually cross-shop it against, since both get framed as mitochondrial-support research and often show up in the same conversations.
| MOTS-c | SS-31 | |
|---|---|---|
| Main angle | Cellular energy signaling, insulin sensitivity, exercise mimicry | Structural protection of the mitochondria's inner membrane |
| Human evidence | None for an administered amount; human data is limited to observed blood levels | The most human-tested compound on this site, including one approved use for a rare condition |
| Regulatory status | Not approved for any use; research compound only | Approved under a different name for one specific rare condition; investigational everywhere else |
| What's less established | Whether an administered amount does anything in a healthy person at all | Whether the research-community amount, far below what was studied, does anything meaningful |
Choose MOTS-c if: the exercise-mimetic and metabolic angle is what you're after.
Choose SS-31 if: mitochondrial structural protection is the more specific interest, and you want a compound with considerably more human trial history behind its mechanism, even if not behind the amount typically self-administered.
Stacking the two: commonly discussed together given the shared mitochondrial framing, run on separate schedules rather than one matched protocol. See the SS-31 research notes for pricing and vendor info.
Storage and handling
Lyophilized powder: refrigerate, or freeze at around -20°C for long-term storage, and protect from light. Commonly described as stable 12 to 24 months when refrigerated.
Reconstituted solution: refrigerate, and plan to use it within about 2 to 4 weeks, a shorter window than many peptides.
Signs of degradation:
- Cloudiness or visible particles in a solution that was previously clear
- Discoloration of the powder or reconstituted liquid
- A course that produces none of the previously noticed subjective effects, though this is a soft signal at best
FAQ
Is there a human study behind the dosing figures? No. Everything circulating is community and vendor convention, extrapolated from animal work, not traced to a human dose-finding study.
How long is a typical course? Most commonly 8 to 12 weeks, followed by a 4 to 6 week break, though the ratio has no traceable source.
Does timing around exercise matter? Some sources dose on workout days on the reasoning that it mirrors natural release, but that's a mechanism-based idea rather than a tested finding.
Is it safe to combine with SS-31? No dedicated combination study exists. The two are commonly discussed together given the shared mitochondrial framing, run on separate schedules.
Is there a concern around blood sugar? It's worth extra caution for anyone managing diabetes or another blood-sugar condition, given the compound's proposed mechanism, and for anyone stacking it with something else that affects blood sugar.
Is there human safety data? No completed human safety study exists for an administered amount. Treat tolerability as an open question.
How is it stored? Refrigerated or frozen as a powder, refrigerated and used within 2 to 4 weeks once reconstituted.
What's the difference between a 2 mg and 5 mg vial? Only the concentration and how many vials your course requires; the reconstitution calculator handles the arithmetic either way.
Bottom line
Key dosing takeaways:
- 5 to 10 mg weekly, split across 2 to 3 injections, is the amount most commonly referenced, though none of it traces to a human study
- MOTS-c is genuinely newer than most compounds on this site in terms of human evidence, which is worth weighing before treating any specific number as settled
- Anyone managing blood sugar should treat this one with particular caution given the proposed mechanism
Best practices:
- Comparing vendors by course total in milligrams, not by vial count, is where the real price differences show up
- Logging each injection keeps a multi-week course from relying on memory
- A rest period between courses is standard across every version of this protocol, even without a traceable source for the specific ratio
Works best for people who:
- Are drawn to the metabolic and exercise-mimetic angle first
- Are comfortable with real uncertainty, since this compound has less human evidence behind it than most others on this site
- Want to research it alongside SS-31 as part of a broader mitochondrial-focused interest